IRIS
BRAVACCINI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.148
AS - Asia 1.381
EU - Europa 738
SA - Sud America 546
AF - Africa 33
OC - Oceania 2
Totale 4.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.098
SG - Singapore 651
BR - Brasile 485
HK - Hong Kong 391
IE - Irlanda 311
VN - Vietnam 124
IT - Italia 99
DE - Germania 91
TR - Turchia 54
FR - Francia 42
CN - Cina 41
NL - Olanda 34
GB - Regno Unito 32
BD - Bangladesh 30
AR - Argentina 27
FI - Finlandia 26
IN - India 25
CA - Canada 24
MX - Messico 22
RU - Federazione Russa 22
AT - Austria 16
IQ - Iraq 15
LT - Lituania 11
UA - Ucraina 11
CO - Colombia 9
PK - Pakistan 9
ZA - Sudafrica 9
ES - Italia 8
PL - Polonia 8
TN - Tunisia 8
BE - Belgio 6
CZ - Repubblica Ceca 6
EC - Ecuador 6
EG - Egitto 6
ID - Indonesia 6
JP - Giappone 6
UZ - Uzbekistan 6
CL - Cile 5
PY - Paraguay 5
SA - Arabia Saudita 5
SE - Svezia 5
VE - Venezuela 5
SN - Senegal 4
AZ - Azerbaigian 3
IL - Israele 3
MA - Marocco 3
AL - Albania 2
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
KE - Kenya 2
KG - Kirghizistan 2
LB - Libano 2
RS - Serbia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
TT - Trinidad e Tobago 1
Totale 4.848
Salva come PNG Salva come JPEG
Città #
Dallas 1.333
Hong Kong 389
Singapore 372
Dublin 311
Santa Clara 138
Boardman 134
The Dalles 122
Ashburn 96
Ho Chi Minh City 47
São Paulo 47
Istanbul 43
Munich 38
Assago 32
Amsterdam 23
Helsinki 23
Rio de Janeiro 22
Beijing 20
Hanoi 20
Los Angeles 18
Frankfurt am Main 17
Brasília 12
Belo Horizonte 10
Boston 10
Chicago 10
Milan 10
Vienna 10
Düsseldorf 9
Haiphong 9
Montreal 9
New York 9
Porto Alegre 9
San Francisco 9
Brooklyn 7
Campinas 7
Ankara 6
Bexley 6
Brno 6
Brussels 6
Buenos Aires 6
Guarulhos 6
Mexico City 6
Paris 6
Salvador 6
Tokyo 6
Toronto 6
Warsaw 6
Atlanta 5
Chennai 5
Lahore 5
Lugo 5
Manchester 5
Nuremberg 5
Quito 5
Stockholm 5
Tashkent 5
Thái Bình 5
Asunción 4
Bogotá 4
Contagem 4
Curitiba 4
Dakar 4
Dhaka 4
Hải Dương 4
Juiz de Fora 4
New Delhi 4
Ottawa 4
Piracicaba 4
Ribeirão Preto 4
Riyadh 4
Rome 4
Roubaix 4
Sorocaba 4
Teresina 4
Atibaia 3
Baku 3
Betim 3
Birmingham 3
Biên Hòa 3
Cairo 3
Cape Town 3
Denver 3
Erbil 3
Hortolândia 3
Houston 3
Itaquaquecetuba 3
Johannesburg 3
João Pessoa 3
Lauterbourg 3
Limeira 3
London 3
Maceió 3
Maricá 3
Milwaukee 3
Nova Iguaçu 3
Osasco 3
Palhoça 3
Passo Fundo 3
Pescara 3
Portsmouth 3
Recife 3
Totale 3.646
Salva come PNG Salva come JPEG
Nome #
The current status of biomarkers for bladder cancer: progress and challenges 138
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. 79
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 79
Expanding the Horizon of Multidisciplinarity: Incorporating Biomechanical, Metabolic, and Functional Factors Into Registry-Based Research to Predict Subsequent Risk for Total Knee Arthroplasty 69
Biomarkers: which ones do we really need today? 66
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 58
The use of platelets as a clinical tool in oncology: opportunities and challenges 57
Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer 57
A functional survey of the regulatory landscape of estrogen-receptor-positive breast cancer evolution 56
Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study 55
A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors 53
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 52
Decoding the NRF2–NOTCH Crosstalk in Lung Cancer—An Update 51
Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit) 49
Androgen receptor signaling pathways as a target for breast cancer treatment 48
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 48
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer 48
FAP inhibitors: are we really using the best method to evaluate the residence time? 46
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 46
Androgen receptor in breast cancer: The "5W" questions 46
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 45
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 45
Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment? 44
An initiative to assess the quality of Tanzanian cervical cancer specimens for HPV and telomerase detection 43
Letter to the Editor discussing: Hacker S, Lenz C, Reichert L, Ringseis R, Zentgraf K, Krüger K. Vitamin D status and its determinants in German elite athletes. Eur J Appl Physiol. 2025 Jan 4. doi: 10.1007/s00421-024–05699-6 43
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma insitu treated with surgery and radiotherapy 43
An H-1 NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia 43
Urinary Biomarkers in Tumors: An Overview 42
Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota 41
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients 41
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer? 41
ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA 40
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 40
Explaining the aggressiveness of breast cancer in sub-Saharan African patients 40
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 40
Microenvironmental determinants of cancer progression during obesity: emerging evidence and novel perspectives 40
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy 40
Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension 39
Are we ready to use TMB in breast cancer clinical practice? 39
Telomerase Activity Analysis In Urine Sediment for Bladder Cancer 39
Evaluating the appropriateness of chemotherapy in a low-resource cancer centre in sub-Saharan Africa 38
TMB in NSCLC: A Broken Dream? 38
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial 38
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in patients with different subtypes of breast cancer 38
Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer 38
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 38
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 37
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 37
Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential 37
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients 37
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 36
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 36
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 36
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity 36
Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR) 36
Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance 36
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 36
Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients. 36
Usefulness of immunological detection of the human telomerase reverse transcriptase 35
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design 35
Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study 35
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer 35
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease. 34
Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer? 34
New Biomarkers to Predict the Evolution of In Situ Breast Cancers 34
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 33
Relevance of urine telomerase in the diagnosis of bladder cancer 33
Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer" 33
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells 32
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia? 32
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data 32
Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma 32
Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR) 31
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 31
Expanding Roles of De Novo Lipogenesis in Breast Cancer 31
In-111-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance 31
The current status of biomarkers for bladder cancer: progress and challenges 31
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 31
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer 31
Why the complications of COVID-19 patients differ in elderly and young cancer patients 31
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 31
What to look for in cell-free DNA from breast cancer patients 30
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression 30
Urine telomerase: An important marker in the diagnosis of bladder cancer 29
Unraveling the protein kinase C/NDRG1 signaling network in breast cancer. 29
Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro 29
Setting Up a Medical Oncology Educational Program in Sub-Saharan Africa 28
Combined analysis of miR-200 family and its significance for breast cancer 28
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis 28
Spotlight on PSMA as a new theranostic biomarker for bladder cancer 28
International consensus on severe lung cancer-the first edition 28
No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country 28
Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold 28
Sorafenib for the treatment of breast cancer 28
Erratum to: Benefit from anthracyclines in relation to biological profiles in early breast cancer 28
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer 27
The current role of telomerase in the diagnosis of bladder cancer 27
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer A case report 27
Role of Telomerase in Cervical Lesions as Prognostic Marker: A Comparison Between Immunohistochemistry and Fluorescence In Situ Hybridization 27
Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients 27
Totale 3.975
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024187 0 0 0 0 0 0 0 0 0 0 0 187
2024/20252.496 264 71 193 57 234 318 149 135 304 299 283 189
2025/20262.426 313 965 545 415 150 38 0 0 0 0 0 0
Totale 5.109